Genesis Biopharma, Inc. (OTCBB: GNBP) is developing autologous cell therapies for the treatment of cancer.
Their lead product candidate, Cōntego™, is an autologous cell therapy using tumor infiltrating lymphocytes (TILs) indicated for the treatment of metastatic melanoma. Cōntego™ is being developed as a ready-to-infuse autologous cell therapy product. Following resection of the patient's tumor, TILs are isolated from the resected tumor, and expanded in vitro to several billion cells. The expanded TILs are then infused into the patient where they attack the melanoma tumors regardless of their location in the body.
Cōntego™ is based on the adoptive cell therapy regimen using tumor infiltrating lymphocytes invented by Dr. Steven A. Rosenberg, Chief, Surgery Branch, Center for Cancer Research, National Cancer Institute for the treatment of metastatic melanoma. Dr. Rosenberg's adoptive cell therapy is presently available as a physician-sponsored investigational therapy for the treatment of Stage IV metastatic melanoma at the National Cancer Institute, MD Anderson Cancer Center, and the H. Lee Moffitt Cancer & Research Institute.
Technology
· Lymphocytes with anti-tumor activity (TILs) migrate into tumor during tumor growth.
· TILs are isolated from tumor, grown ex vivo to great numbers, and infused back into patient.
· TILs are cultured ex vivo away from suppressive in vivo influences, enabling administration of highly activated cells with strong anti-tumor effector functions.
· Patient is preconditioned to remove all suppressive influences prior to infusion of ex vivo cultured TILs to enhance therapeutic outcome.
To view full Company Profile CLICK HERE
About OTCPicks.com
OTCPicks.com is an Internet destination for investors seeking information on small cap and micro-cap companies. The web site features companies in Profile Campaigns, Executive Interviews and Research Reports authored by our financial writers. We publish our Daily Market Movers Digest Newsletter to opt-in investor members. To feature a company on OTCPicks.com, please contact our publisher at 972-546-3740, or via email at publisher@otcpicks.com.
Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk.
